About BCT

About BCT


BCT, founded in 2000, is a clinical-stage biopharmaceutical company focused on the research and development of innovative biologics for the treatment of human malignancies and auto-immune disorders.

The company’s product candidate portfolio comprises BCT-100 and BCT-200, both pegylated recombinant human arginase 1 (pegArg1), are arginine depleting agents that retard tumor growth and ultimately lead to cancer death. BCT-100 is currently in phase I clinical trial in the US for the treatment of arginine-auxotrophic solid cancers and phase II clinical trials in United Kingdom for the treatment of acute myeloid leukemia (AML) in combination with low dose cytarabine in elderly patients and in sarcomas, AML and neuroblastoma in pediatric patients.


To develop innovative bio-therapeutics for safe and effective treatments of multiple cancer indications and auto-immune disorders.



Subject Matters of Patents Granted